Seqirus, a global innovator in influenza vaccines, is expanding its global headquarters in Maidenhead to support its rapid growth. It has outgrown its original offices – opened three years ago by constituency MP Theresa May – due to its continuing global expansion. Over the past two years, the number of employees at Seqirus headquarters has doubled to over 220 staff.
The extensive new, high-technology offices in Maidenhead town centre, adjacent to the current Seqirus HQ, total 25,000 sq ft and have capacity for up to an additional 250 employees. Cutting the ribbon, Seqirus president Gordon Naylor said: “I am very pleased to open this new office, which will strengthen our ability to support our swiftly growing influenza vaccines business across the globe. I think our employees will be grateful too, as it was getting a little cramped in our original building.”
Expansion in Maidenhead follows announcements this year of major new investments in the company’s Liverpool manufacturing plant – one of the largest in Europe – and at its Holly Springs production site in North Carolina. In total, Seqirus plans to add up to 200 new jobs in the UK to its current workforce of 900 over the next two years.
David Sheppard, deputy head of life sciences at the Department for International Trade, said: “We were pleased to work with Seqirus to establish their presence in Maidenhead and welcome the news of the company’s ongoing expansion. The life sciences sector is an important to the UK and we are committed to supporting its continued growth, particularly both in terms of exports and inward investment.”
Councillor Paul Lion, mayor of the Royal Borough of Windsor and Maidenhead, said: “We are delighted that Seqirus is creating more highly skilled jobs here in Maidenhead. This is the kind of success story that will help Maidenhead build its position as a science and technology hub in the Thames Valley.”
Naylor commented: “We are not only adding jobs here in Maidenhead, but also in Liverpool and at other Seqirus sites around the globe. We are achieving this by making world-class influenza vaccines, which help prevent serious illness, save lives and relieve winter pressures on health systems around the world.”